US · DNLI
Denali Therapeutics Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- South San Francisco, CA 94080
- Website
- denalitherapeutics.com
Price · as of 2025-12-31
$18.30
Market cap 3.31B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | $20.37 | ||||
| 2018 | $20.61 | $4.47 | $3.95 | ||
| 2019 | $18.18 | $61.26 | $1.51 | $0.00 | $140.17 |
| 2020 | $64.69 | $251.21 | $10.24 | $13.82 | $728.48 |
| 2021 | $30.39 | $43.48 | $4.94 | $0.00 | $176.34 |
| 2022 | $23.22 | $39.86 | $60.66 | $0.00 | $0.00 |
| 2023 | $20.93 | $47.40 | $113,010.93 | $2.22 | $0.00 |
| 2024 | $16.69 | $31.91 | |||
| 2025 | $21.00 |
AI valuation
Our deep-learning model estimates Denali Therapeutics Inc.'s (DNLI) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $18.30
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| DNLI | Denali Therapeutics Inc. | $18.30 | 3.31B | — | — | — | — | -7.19 | 3.63 | — | -5.73 | -46.19 | 3.63 | 0.00% | — | — | -45.69% | -177.80% | -40.69% | 0.03 | — | 9.16 | 8.82 | 0.35 | 1556.00% | — | 1609.00% | -11.46% | -4.20 | -135.14% | 0.00% | 0.00% | 1.26% | -5.13 | -6.75 | — | 13.60 |
| AGIO | Agios Pharmaceuticals, In… | $30.23 | 1.77B | -31% | +212% | — | — | -4.10 | 1.42 | 31.33 | -1.93 | — | 1.42 | 88.26% | -873.87% | -764.01% | -30.20% | -85.25% | -27.89% | 0.05 | — | 11.46 | 10.52 | 0.06 | -16117.00% | 4803.00% | -364.00% | -22.29% | -4.54 | -68.29% | 0.00% | 0.00% | 0.46% | -1.91 | -2.39 | 16.67 | 8.79 |
| BEAM | Beam Therapeutics Inc. | $28.46 | 2.89B | +40% | +284% | -70% | — | -35.47 | 2.29 | 20.31 | -63.04 | — | 2.29 | 84.05% | -274.57% | -57.24% | -8.11% | -231.66% | -6.19% | 0.24 | -8.77 | 13.09 | 12.85 | 0.04 | -8231.00% | 12001.00% | 108.00% | -12.69% | -3.56 | -217.38% | 0.00% | 0.00% | 0.00% | -4.92 | -5.24 | 13.50 | 5.65 |
| COGT | Cogent Biosciences, Inc. | $38.85 | 6.31B | — | — | — | — | -7.99 | 4.13 | — | -6.03 | -218.46 | 4.13 | 0.00% | — | — | -73.70% | 2714.02% | -51.99% | 0.40 | -108.87 | 14.23 | 14.08 | 0.18 | 366.00% | — | 2766.00% | -10.12% | -4.13 | 2165.58% | 0.00% | 0.00% | 0.00% | -5.94 | -7.45 | — | 3.37 |
| GLPG | Galapagos N.V. | $33.66 | 2.22B | +251% | +430,280% | +154% | +4,930% | 6.01 | 0.60 | 1.73 | -1.90 | 1.80 | 0.60 | 93.49% | 40.56% | 28.85% | 10.47% | 2205.83% | 8.51% | 0.00 | 164.04 | 20.15 | 19.95 | -0.14 | 33304.00% | 30348.00% | -4967.00% | -10.50% | -1.24 | -989.65% | 0.00% | 0.00% | 1.20% | -2.34 | 5.22 | -0.95 | 8.66 |
| IBRX | ImmunityBio, Inc. | $9.78 | 9.63B | +901% | -57% | — | — | — | -19.22 | 84.77 | -45.80 | — | -18.70 | 99.34% | -226.00% | -310.18% | 0.00% | -52123.97% | 0.00% | -1.76 | -2.28 | 5.10 | 4.62 | -3.53 | -3871.00% | 66831.00% | -2341.00% | -3.18% | -4.94 | -62105.09% | 0.00% | — | 0.00% | -39.99 | -33.58 | 90.38 | -5.49 |
| LQDA | Liquidia Corporation | $31.02 | 2.7B | -15% | +1,142% | — | -41% | -8.95 | 15.09 | 83.34 | -9.61 | -24.05 | 16.61 | 58.00% | -866.63% | -931.65% | -209.35% | -667.62% | -74.80% | 1.58 | -9.71 | 4.43 | 4.29 | 0.47 | 3719.00% | -1997.00% | 12955.00% | -8.43% | -2.24 | -541.45% | 0.00% | 0.00% | 1.71% | -9.17 | -11.31 | 79.48 | 0.24 |
| RCUS | Arcus Biosciences, Inc. | $20.37 | 2.05B | +8% | -43% | — | — | -7.28 | 4.07 | 10.41 | -5.04 | -152.47 | 4.07 | 95.95% | -156.28% | -142.91% | -63.26% | 112.87% | -30.84% | 0.16 | -48.25 | 4.36 | 4.25 | 0.37 | 478.00% | -426.00% | 17500.00% | -18.82% | -2.09 | 141.52% | 0.00% | 0.00% | 1.28% | -4.38 | -3.49 | 6.84 | 1.13 |
| RXRX | Recursion Pharmaceuticals… | $3.67 | 1.47B | +586% | +721% | — | — | -2.52 | 1.44 | 21.75 | -1.71 | — | 2.47 | -61.96% | -867.87% | -863.35% | -59.54% | -127.75% | -44.12% | 0.07 | -358.08 | 5.50 | 5.20 | 1.19 | -1479.00% | 2692.00% | 145.00% | -23.29% | -2.52 | -74.58% | 0.00% | 0.00% | 11.05% | -1.48 | -2.53 | 12.84 | 0.01 |
| VRDN | Viridian Therapeutics, In… | $29.38 | 2.39B | +11,973% | +7,221% | — | — | -7.49 | 3.55 | 36.21 | -5.16 | — | 3.55 | 98.36% | -512.91% | -483.57% | -49.16% | 573.89% | -41.73% | 0.07 | -73.44 | 12.65 | 12.37 | 0.48 | -1658.00% | 2335993.00% | 1892.00% | -10.79% | -3.91 | 437.27% | 0.00% | 0.00% | 3.24% | -4.79 | -6.29 | 24.58 | 6.44 |
About Denali Therapeutics Inc.
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreement with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
- CEO
- Ryan J. Watts
- Employees
- 443
- Beta
- 1.02
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $18.30) − 1 = — (DCF, example).